Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harmony Biosciences Holdings Inc HRMY

Healthcare
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance... see more

Recent & Breaking News (NDAQ:HRMY)

Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

PR Newswire January 5, 2022

Harmony Biosciences to be Added to the Nasdaq Biotech Index

PR Newswire December 17, 2021

Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs

PR Newswire December 13, 2021

Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia

PR Newswire December 1, 2021

Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors

PR Newswire November 22, 2021

Harmony Biosciences To Participate In Two Investor Conferences In November

PR Newswire November 11, 2021

Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates

GlobeNewswire November 9, 2021

Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results

PR Newswire October 26, 2021

Harmony Biosciences to be Added to the S&P SmallCap 600® Index

PR Newswire October 21, 2021

Kite Realty Group Trust Set to Join S&P MidCap 400; Harmony Biosciences Holdings & LendingTree to Join S&P SmallCap 600

PR Newswire October 18, 2021

Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy Day

PR Newswire September 22, 2021

Harmony Biosciences Announces Inclusion Of WAKIX® (pitolisant) In American Academy Of Sleep Medicine's Updated Clinical Practice Guideline

PR Newswire September 2, 2021

Harmony Biosciences To Participate In Three Investor Conferences In September

PR Newswire September 2, 2021